Skip to content
DataLookout
Menu

NCT07783581

Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Eligibility criteria expanded, about 19 words
    • Primary completion pushed from Apr 1, 2030 to Jun 1, 2030
    • Study completion pushed from Apr 1, 2030 to Jun 1, 2031
    • Start date changed from estimate of Sep 7, 2026 to Nov 4, 2026
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Improvement in major pathologic response rate (MPR)
Timeframe: At the time of surgical resection

Secondary (3)

Pathologic complete response rate
Percent of patients receiving the prescribed therapy
Incidence of Adverse Events (AEs) Prior to Surgery:

Arms and interventions

Arm A (proton SFRT, pembrolizumab, surgery)Experimental

Patients receive proton SFRT QOD for up to 3 treatment fractions over 1 week. Starting within 7 days of initiating SFRT, patients receive pembrolizumab IV on day 1 of each cycle. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within 8 weeks of completing pembrolizumab, patients undergo surgical resection per standard of care. Patients also undergo blood sample collection, CT, and PET/MRI or PET/CT throughout the study. Additionally, patients may also undergo tissue biopsy at baseline and/or on study.

Arm B (photon SBRT, pembrolizumab, surgery)Experimental

Patients receive photon SBRT QOD for up to 3 treatment fractions over 1 week. Starting within 7 days of initiating SBRT, patients receive pembrolizumab IV on day 1 of each cycle. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within 8 weeks of completing pembrolizumab, patients undergo surgical resection per standard of care. Patients also undergo blood sample collection, CT, and PET/MRI or PET/CT throughout the study. Additionally, patients may also undergo tissue biopsy at baseline and/or on study.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure

Biologicals: Pembrolizumab

Radiation: Photon Stereotactic Body Radiation Therapy, Spatially-fractionated Radiation Therapy

Sites

1 site in 1 country

  • Mayo Clinic in RochesterRochester, Minnesota, United States